Management Team.

Neil Sankar, MD MPH

Chief Medical Officer & Global Medical Lead

Neil has over 16 years of experience in life sciences clinical development, including pipeline strategy, clinical safety, pharmacovigilance, and US Food and Drug Administration regulations and applications.

President and Chief Medical Officer of the consultancy firm SwanBio LLC, Neil facilitates the translation of scientific discoveries into cancer therapeutics and provides global clinical development and regulatory strategies for Drug approvals leading to commercialization. An expert in evaluating clinical trial efficacy and safety, he has acted as medical lead in multiple phase I, II, and III clinical trials with a specialization in oncology, and serves as a member of drug safety committees and advisory boards for numerous companies, including Leukemia Therapeutics and iNDX Technology. He has held clinical development positions at a number of leading Biotech/Pharma companies, including Genentech, MedImmune, Pharmacyclics, Five Prime Therapeutics, Inc., Portola Pharmaceuticals, Loxo Oncology, Inc., Otsuka Pharmaceuticals, Elevar Therapeutics, Boston Biomedical, Inc, BMS,Teon Therapeutics, Jasper Therapeutics, Seneca Therapeutics, eFFECTOR Therapeutics, Edison Oncology, Rakovina Therapeutics, and Rhizen Pharmaceuticals AG.

Neil is a member of the American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), European Hematology Association (EHA), Drug Information Association (DIA), European Society Of Clinical Oncology (ESMO), American Association For Cancer Research (AACR), Enterprising Pharmaceutical Professionals from the Indian Sub-Continent (EPPIC GLOBAL), Connective Tissue Oncology Society (CTOS), Indo-American Cancer Association (IACA), Society for immunotherapy of Cancer (SITC), The North American endocrine Tumor Society (NANETS), and TiE Silicon Valley. He received his MD from Bangalore University; completed his internal medicine residency at the University of West Indies, Kingston, Jamaica; and trained in clinical research and tumor biology at National Cancer Institute in Bethesda, Maryland. He earned his MPH at Queensland University in Australia.